Aspira Pathlab & Diagnostics Ltd Valuation
ASPIRA · Healthcare Services · Current price ₹97
Is Aspira Pathlab & Diagnostics Ltd undervalued?
DocStoX estimates the fair value of Aspira Pathlab & Diagnostics Ltd at ₹15 per share, versus the current market price of ₹97. That puts the stock about -84.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹15). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹13 (bear) to ₹15 (base) to ₹17 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
Aspira Pathlab & Diagnostics Ltd trades at a P/E of 48.3x and a P/B of 7.5x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on Aspira Pathlab & Diagnostics Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.